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Report
frontal cortex, and amygdala play a central role in both
acute and chronic responses to addictive drugs (Spana-
gel and Weiss, 1999) and may represent an important
Corticotropin-Releasing Factor Requires
CRF Binding Protein to Potentiate NMDA Receptors
via CRF Receptor 2 in Dopamine Neurons
site of interaction between stress and drug abuse, since
stressful stimuli or intra-cerebro-ventricular (icv) infu-
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2 Wheeler Center for the Neurobiology of Addiction sions of CRF increase dopamine release in both limbic
and cortical projection areas (Dunn and Berridge, 1987;University of California, San Francisco
San Francisco, California 94110 Koob and Heinrichs, 1999). How CRF modulates dopa-
minergic activity, however, is unclear.
The VTA dopamine neurons are under important regu-
latory control from excitatory glutamatergic projections,Summary
and modulation of these synapses is involved in both
short- and long-term changes in dopaminergic activityStress increases addictive behaviors and is a common
(Bonci and Malenka, 1999). Interestingly, stress-inducedcause of relapse. Corticotropin-releasing factor (CRF)
activation of the dopamine system requires NMDAR ac-plays a key role in the modulation of drug taking by
tivity (Morrow et al., 1993), and repeated stress inducesstress. However, the mechanism by which CRF modu-
increases in NMDAR and -amino-3-hydroxy-5-methyl-lates neuronal activity in circuits involved in drug ad-
isoxazolepropionic acid receptor (AMPAR) subunits indiction is poorly understood. Here we show that CRF
the VTA (Fitzgerald et al., 1996). Although studies haveinduces a potentiation of NMDAR (N-methyl-D-aspar-
shown that CRF modulates neuronal excitability in thetate receptor)-mediated synaptic transmission in do-
hippocampus and locus coeruleus, respectively (Alden-pamine neurons of the ventral tegmental area (VTA).
hoff et al., 1983; Valentino et al., 1983), the role of CRFThis effect involves CRF receptor 2 (CRF-R2) and acti-
in the modulation of excitatory synaptic transmissionvation of the phospholipase C (PLC)-protein kinase C
is poorly understood. In the current study we directly(PKC) pathway. We also find that this potentiation re-
examined the effects of CRF on NMDAR-mediated syn-quires CRF binding protein (CRF-BP). Accordingly,
aptic transmission onto dopamine neurons in an in vitroCRF-like peptides, which do not bind the CRF-BP with
VTA slice preparation.high affinity, do not potentiate NMDARs. These results
provide evidence of the first specific roles for CRF-R2
Resultsand CRF-BP in the modulation of neuronal activity and
suggest that NMDARs in the VTA may be a target for
We measured excitatory postsynaptic currents (EPSCs)both drugs of abuse and stress.
recorded in putative dopamine neurons in midbrain
slices from mice. EPSCs were evoked while holdingIntroduction
neurons in voltage clamp at 40 mV; measurements
were taken at a time point when the EPSC is purelyCorticotropin-releasing factor (CRF), a 41 amino acid
NMDAR mediated (Ungless et al., 2001). To test thepeptide, plays an obligatory role in the activation of the
hypothesis that CRF could modulate NMDAR-mediatedhypothalamic-pituitary-adrenal axis and the subsequent
EPSCs recorded from VTA neurons, we then bath ap-release of glucocorticoids in response to stressful events
plied CRF (0.01–1 M). The application of CRF resulted(Shaham et al., 2000). In addition, extrahypothalamic
in a concentration-dependent potentiation of NMDAR-CRF mediates many behavioral responses to stress
mediated EPSCs in VTA neurons that was transient and(Koob and Heinrichs, 1999). At the cellular level, release
slow to develop (10 nM: 99.26  20.03, n  4; 100 nM:of CRF activates two receptors, CRF-R1 and CRF-R2
125.81  9.39, n  10; 1 M: 139.82  18.38 (n  7)(Dautzenberg and Hauger, 2002). CRF also binds to a
mean  SEM, Figure 1A). However, this effect was notbinding protein (CRF-BP), which has been shown to
seen in all the neurons (Figure 1A, middle panel), sug-inactivate “free” CRF in the periphery (Linton et al.,
gesting the presence of distinct subpopulations of CRF-1990). Although a high level of CRF-BP has been de-
responding and non-CRF-responding neurons. To facili-tected in the central nervous system, its exact role is
tate our subsequent investigation of the effects of CRF,not clear (Kemp et al., 1998).
we sought to find a characteristic that might help usCRF is thought to be a key link between the behavioral
identify, a priori, CRF-responsive neurons. The majorityand physiological effects of stress and drugs of abuse
of neurons in the VTA are dopaminergic and express Ih,(Shaham et al., 2000). The dopaminergic neurons of the
a hyperpolarization-activated inward current. This cur-ventral tegmental area (VTA) and their widespread pro-
rent is commonly used to identify putative dopaminejections to areas such as the nucleus accumbens, pre-
neurons (e.g., Bonci and Malenka, 1999). However, it
has previously been shown that these neurons can be
*Correspondence: bonci@itsa.ucsf.edu divided into subgroups based on the size of the Ih; cal-3 These authors contributed equally to this work.
bindin-expressing dopamine neurons have a smaller Ih4 Present address: MRC Anatomical Neuropharmacology Unit, De-
current than those that do not contain calbindin (Neuhoffpartment of Pharmacology, University of Oxford, Mansfield Road,
Oxford, OX1 3TH, England. et al., 2002). In our study, we noticed that, typically,
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Figure 1. CRF Potentiates NMDAR-Medi-
ated Synaptic Transmission in Dopamine
Neurons with a Large Ih
Filled circles correspond to large Ih neurons,
and open circles correspond to small Ih neu-
rons. (A) (Upper and central panel) Examples
of the effect of CRF on NMDAR-mediated
EPSCs in two dopamine neurons. Scale bars,
20 pA, 40 ms. (Lower panel) Summary bar
graph demonstrating the concentration-
dependent potentiation of NMDAR EPSCs in
large Ih neurons (0.01, 0.1, and 1 M) n  4,
n  11, and n  7, respectively. The columns
show that both 100 nM CRF and 1 M pro-
duced a significant potentiation of NMDA cur-
rent amplitude (*p  0.05). (B) Examples of Ih
from both types of neuron. Ih is computed as
the difference between time points 1 and 2.
(C) Large Ih neurons exhibit CRF-induced po-
tentiation of NMDAR-mediated EPSCs. Small
Ih neurons do not exhibit CRF-induced poten-
tiation. Left axis represents the magnitude of
the effect of CRF on NMDAR-mediated
EPSCs (20–30 min), plotted against Ih size on
the horizontal. Right axis represents fre-
quency of cells in 10 pA bins of Ih. Dopamine
neurons form a bimodal distribution of Ih size,
which corresponds to the CRF and non-CRF
responsive groups. (D) (Upper panel) Sum-
mary of responses to 1 M CRF in large Ih
(n  7) and small Ih (n  8) neurons. (Lower
panel) CRF does not potentiate AMPAR-me-
diated EPSCs. Scale bars, 40 pA, 5 ms (n 
4). *p  0.05 versus baseline.
neurons that responded to CRF had large Ih currents via CRF-R1 activation (Sillaber et al., 2002). In this case,
the effect of CRF was blocked by coapplication of 3 M(Figure 1B). A subsequent analysis found that Ih size
was a strong predictor of CRF response (Figure 1C). CP-154,526 (CRF 1 M: 143.0%  7.7% 15 min after
CRF onset, n  4, p  0.05; CRF plus CP-154,526:A frequency histogram of 199 neurons shows that Ih
distribution can be fitted well with a bimodal distribution, 82.9%  6.9%, n  5, p  0.05). In contrast with the
effect of CP-154,526 in the VTA, the presence of a selec-suggesting the existence of two subpopulations of cells
that correspond to the Ih distribution of CRF-responding tive CRF-R2 antagonist (Antisauvagine-30; Ruhmann et
al., 1998; 1 M for 15 min) inhibited the CRF-inducedand non-CRF-responding cells (Figures 1C and 1D, up-
per panels). Henceforth, all subsequent experiments potentiation in the VTA (Figure 2B). We further tested
the receptor selectivity of this effect by using a lowerwere conducted on cells with an Ih greater than 100 pA.
CRF could potentiate NMDAR-mediated EPSCs in the concentration of Antisauvagine-30 (30 nM). In the pres-
ence of this lower concentration, CRF did not signifi-VTA via a presynaptic effect on glutamate release, a
postsynaptic modification of the NMDAR, or both. If CRF cantly potentiate NMDAR-mediated EPSCs (113.9% 
17.7%; 15 min after CRF onset, n  3, p  0.05). Takenacts presynaptically to increase glutamate release, then
we should also observe an increase in AMPAR-mediated together, these results strongly suggest that CRF signals
through CRF-R2 to potentiate NMDAR-mediated EPSCssynaptic transmission. When we measured AMPAR-
mediated EPSCs while holding neurons in voltage clamp in the VTA.
Although low levels of CRF-R1 mRNA have been foundat 70 mV, CRF did not potentiate AMPAR-mediated
EPSCs (Figure 1D, lower panel). This suggests that the in the VTA using in situ hybridization techniques, CRF-
R2 mRNA has been reported to be absent (Van Pett eteffect of CRF on NMDAR-mediated EPSCs likely in-
volves modulation of postsynaptic NMDARs. al., 2000). Since our results indicate the presence of
CRF-R2 in the VTA, we attempted to detect a CRF-R2Next, we sought to determine the receptor subtype
through which CRF potentiates NMDAR currents in the message in the VTA using reverse transcription-poly-
merase chain reaction (RT-PCR). In agreement with ourVTA. CRF binds to two types of receptor: CRF-R1 and
CRF-R2 (Dautzenberg and Hauger, 2002). A selective pharmacological experiments, we found detectable lev-
els of CRF-R2 mRNA in the VTA (Figure 2C) when com-CRF-R1 antagonist (CP-154,526; Schulz et al., 1996; 3
M for 15 min) failed to block the effects of CRF (Figure pared to the septum, which expresses a high level of
the receptor, and the cerebellum, which does not ex-2A) even at this relatively high concentration. To confirm
that CP-154,526 was active, we tested its effects in the press CRF-R2 mRNA (Van Pett et al., 2000). To further
determine if the CRF-R2 mRNA was present in the largehippocampus, where CRF potentiates field potentials
CRF Modulation of Dopamine Neurons
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Figure 2. CRF-Induced Potentiation of
NMDAR-Mediated Synaptic Transmission
Requires CRF-R2, Phospholipase C, and
PKC
Filled bars denote CRF application; open bars
denote application of antagonist in title of
each panel. (A) CRF-R1 antagonist CP-
154,526 does not block CRF-induced potenti-
ation of NMDAR-mediated EPSCs (n 6). (B)
CRF-R2 antagonist Antisauvagine-30 blocks
CRF-induced potentiation of NMDAR-medi-
ated EPSCs (n 5). (C) Total RNAs from VTA,
septum, and cerebellar slices were isolated,
and the expression of CRF-R2 and control
GPDH were analyzed by RT-PCR as de-
scribed in Experimental Procedures. PCR
products were separated on an agarose gel
and photographed by Eagle Eye II. Results
are representative of three independent ex-
periments. (D) Two representative examples
(out of 15) of single VTA neurons with large
Ih expressing CRF-R2. PCR products were
separated on a 1.2% agarose gel in parallel
with a 100 bp ladder as molecular weight
marker, positive control (RNA from septum
slices,) and negative control (no sample,).
Inset represents corresponding Ih currents (of
cells 1 and 2) induced by hyperpolarizing volt-
age steps. (E) CRF-induced potentiation of
NMDAR-mediated EPSCs is not blocked by
the cAMP inhibitor Rp-cAMPs (n  4) or the
PKA inhibitor PKI (n  5). (F) CRF-induced
potentiation of NMDAR-mediated EPSCs is
blocked by the phospholipase C inhibitor
U73122 (n 5) or the PKC inhibitor Bisindolyl-
maleimide 1 (n 4). *p 0.05 versus baseline.
Ih VTA neurons, we performed single-cell RT-PCR from way. CRF also binds to a binding protein (CRF-BP),
whose role in the brain is unclear (Kemp et al., 1998).individual VTA large Ih neurons. CRF-R2 mRNA was con-
sistently detected in these neurons (n  15; Figure 2D). CRF-BP is expressed in the VTA (Chan et al., 2000), and
we therefore decided to test the hypothesis that CRF-In the next set of experiments, we tried to identify the
intracellular pathway through which CRF-R2 activation BP inactivates CRF in this brain region. We coapplied
CRF with a CRF fragment (6-33) (1 M for 10 min), whichleads to NMDAR potentiation. CRF-R2 is a seven-trans-
membrane domain, G protein-coupled receptor that can shows high-affinity binding to the CRF-BP but a much
lower affinity than CRF for the CRF receptors (Behansignal through a number of intracellular pathways, most
notably the cAMP-PKA pathway (Dautzenberg and et al., 1995). Consequently, the CRF fragment (6-33)
competes with CRF at the CRF-BP thereby increasingHauger, 2002). However, when we loaded the patch pi-
pette with the cAMP inhibitor Rp-cAMPs (100 M) or the level of “free” CRF, which we expected to result
in an even larger increase in NMDAR-mediated EPSCwith the PKA inhibitor PKI (20 M; PKI administered in
this manner has previously been shown to block PKA- amplitude induced by CRF. Contrary to this expectation,
CRF did not potentiate NMDAR-mediated EPSCs in therelated effects on NMDARs in dopamine neurons; B.
Schilstrom, R.Y., V.S., D.R., and A.B., unpublished data), presence of the CRF fragment (6-33) (Figure 3A). To
exclude the possibility that the CRF fragment had anywe still observed a significant CRF-induced potentiation
of NMDAR-mediated EPSCs (Figure 2E). In the hippo- effect on NMDAR-mediated EPSCs on its own, we bath
applied the fragment in the absence of CRF (Figure 3A).campus, the phospholipase C (PLC)-protein kinase C
(PKC) pathway is involved in the effects of CRF on popu- Under these conditions, we were not able to detect any
effect of the CRF fragment (6-33) on NMDAR-mediatedlation spikes (Blank et al., 2002). Therefore, we tested
whether inhibition of this pathway could interfere with EPSCs. Taken together, these results indicate that CRF-
induced potentiation of NMDAR-mediated EPSCs mightthe CRF-induced potentiation of NMDAR-mediated
EPSCs in the VTA. First, we bath applied the PLC inhibi- require both CRF-R2 and the CRF-BP. Therefore, ovine
CRF, which differs from human/rat CRF by seven aminotor U-73122 (1 M) prior to and during CRF application.
Then, we determined the effect of adding the PKC inhibi- acids, should not produce any potentiation of the
NMDAR-mediated EPSC, because although it bindstor Bisindolylmaleimide 1 (BIS; 1 M) intracellularly to
the patch pipette. In both cases, the potentiation of CRF-R2 with high affinity, it shows a much lower affinity
for CRF-BP. Accordingly, we observed no potentiationNMDAR-mediated EPSCs by 1 M CRF was blocked
(Figure 2F), suggesting that in VTA neurons, CRF po- of NMDAR-mediated EPSCs following application of
ovine CRF (1 M for 8 min; Figure 3B). It appears, then,tentiates NMDARs through a CRF-R2-PLC-PKC path-
Neuron
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Figure 3. CRF Binding Protein Is Necessary
for CRF-Induced Potentiation of NMDAR-
Mediated Synaptic Transmission
Filled bars denote CRF application; open bars
denote application of substance in title of
each panel. (A) CRF fragment (6-33), which
competes with CRF at the CRF-BP but does
not bind CRF-R2, inhibits CRF-induced po-
tentiation of NMDAR-mediated EPSCs (n 
5). (B) Ovine CRF, which binds with high affin-
ity to CRF-R2 but not CRF-BP, does not in-
duce potentiation of NMDAR-mediated
EPSCs (n  5). (C) Urocortin potentiates
NMDARs in cells with large Ih (filled circles)
(n  6) but not those with small Ih (open cir-
cles) (n 3). (D) Urocortin II does not potenti-
ate NMDARs (n  4). (E and F) A cartoon
illustrating the interaction between the CRF
system and NMDARs in dopamine neurons.
(E) When CRF is not bound to CRF-BP, it does
not activate CRF-R2. (F) When CRF is bound
to CRF-BP it can activate CRF-R2 and the
PLC pathway to potentiate NMDARs in dopa-
mine neurons. *p  0.05 versus baseline.
that CRF might somehow interact with the CRF-BP to Discussion
signal through CRF-R2 and potentiate NMDAR-medi-
ated EPSCs. In the present study, we demonstrate that CRF induces
a potentiation of NMDAR-mediated EPSCs in a subsetIt has been suggested that the Urocortin family of
CRF-like peptides may be the endogenous ligands for of VTA neurons containing a large Ih. Our experiments
indicate that this potentiation is mediated by the R2CRF-R2 (Vaughan et al., 1995). Urocortin binds CRF-R2
and the CRF-BP with higher affinity than CRF, while it subtype of CRF receptors and requires the activation
of PLC and PKC. In addition, we present evidence sug-binds CRF-R1 with a slightly lower affinity than CRF-R2;
in contrast, Urocortin II binds selectively to CRF-R2, gesting that the CRF-BP might be necessary for CRF-
induced potentiation of NMDAR-mediated EPSCs.showing low affinity for both CRF-R1 and the CRF-BP
(Reyes et al., 2001). In addition to this preferential bind- The potentiation of NMDAR-mediated EPSCs is con-
centration dependent, with both 1 M CRF and 100ing to CRF-R2, Urocortin and Urocortin II both exhibit
some anatomical overlap with CRF-R2. Given our finding nM but not 10nM, producing significant increases in
NMDAR-mediated EPSCs. Although it is possible thatthat CRF needs to interact with both CRF-R2 and CRF-
BP to potentiate NMDARs, we expected Urocortin, but 1 M CRF might be saturating (Lovenberg et al., 1995), it
is unlikely that the effect of CRF observed in the presentnot Urocortin II, to mimic CRF. Accordingly, we observed
potentiation of NMDAR-mediated EPSCs following ap- study was due to nonspecific actions of CRF. First, the
CRF-induced potentiation of NMDAR currents wasplication of Urocortin (1 M for 8 min; Figure 3C) and
no potentiation of NMDAR-mediated EPSCs following blocked by selective concentrations of a CRF-R2 antag-
onist. Second, it is likely that the concentration of CRFapplication of Urocortin II (1 M for 8 min; Figure 3D).
These results further suggest that the CRF-BP is impor- that reaches receptors in a brain slice preparation is
reduced due to problems with diffusion as well as degra-tant for the ability of CRF (or CRF-like ligands) to potenti-
ate NMDAR function. Based on these results we propose dation of CRF by endogenous enzymes (Ritchie et al.,
2003). Finally, endogenous ligands such as glutamatethe model illustrated in Figures 3E and 3F. We hypothe-
size that when CRF is not bound to the CRF-BP it does are released at concentrations considerably higher than
receptor EC50 values derived from cell lines (Clementsnot activate CRF-R2 (Figure 3E). However, when CRF
is bound to the CRF-BP it can activate CRF-R2 and the et al., 1992). Consequently, we believe that it is likely
that applying CRF at a concentration of 1 M mimicsPLC pathway to potentiate NMDAR-mediated EPSCs in
VTA neurons (Figure 3F). physiologically relevant actions of CRF (except that en-
CRF Modulation of Dopamine Neurons
405
dogenous CRF would be released in such concentra- specifically through the PLC-PKC pathway when bound
to CRF-R2.tions in a highly localized fashion).
The current study also demonstrates that the effect Activation of NMDARs in the VTA plays a key role in
the switch from regular firing to burst firing in dopamineof CRF on NMDAR-mediated EPSCs in the VTA was
likely mediated by CRF-R2. This is supported by the neurons (Overton and Clark, 1997). Burst firing leads to
substantial increases in dopamine levels at projectionobservation that a selective concentration of the CRF-
R2 antagonist Antisauvagine-30 (30 nM) but not a high areas, including the nucleus accumbens, prefrontal cor-
tex, and amygdala, and may be involved in stress-concentration of the CRF-R1 antagonist CP 154,526
(3 M) inhibited the response to CRF in the VTA. In induced activation of the dopamine system, which could
in turn modulate drug-taking behavior (Shaham et al.,addition, we were able to demonstrate the presence of
mRNA for CRF-R2 within the VTA and, more specifically, 2000). Furthermore, a single in vivo cocaine exposure
can induce LTP-like plasticity in dopamine neurons, thewithin large Ih neurons in this brain region. Previous
studies, using in situ hybridization, have demonstrated induction of which can be blocked by NMDAR antago-
nists (Ungless et al., 2001). This, as well as previousthe presence of CRF-R1 but not CRF-R2 in the VTA (Van
Pett et al., 2000). However, it is possible that in our studies, suggested that LTP in the VTA may represent
a common site of action for the long-term consequencesstudy CRF-R2 was detected due to the relatively higher
sensitivity of the RT-PCR amplification technique when of both stress and drugs of abuse (Fitzgerald et al.,
1996). Consistent with this possibility, repeated stresscompared to the in situ hybridization technique.
Surprisingly, the pharmacological data in the current or cocaine increases the expression of NMDAR and
AMPAR subunits in the VTA, and stress also producesstudy suggest that the CRF-BP may be required for CRF
to potentiate NMDAR-mediated EPSCs in the VTA. In plasticity at excitatory synapses onto these neurons
(Fitzgerald et al., 1996; Saal et al., 2003). Althoughparticular, pretreating the slices with the CRF fragment
(6-33) abolished the effect of CRF on NMDAR-mediated the role of CRF in such stress-dependent plasticity at
AMPARs has not yet been investigated, our data indi-EPSCs in the VTA. Although the exact role of CRF (6-33)
is unclear, it is thought to be a high-affinity CRF-BP cate that the potentiation of NMDARs by CRF in the VTA
during stress may facilitate the induction of LTP-likeligand inhibitor that can dissociate both CRF and Uro-
cortin from the CRF-BP while having little biological processes.
The subset of VTA neurons that do respond to CRFactivity on its own and has previously been used as a
CRF-BP inhibitor (Behan et al., 1995; Heinrichs et al., may represent the calbindin-negative DA neurons (Neu-
hoff et al., 2002). The VTA contains CRF-immunoreactive1996; Jahn et al., 2002). The hypothesis that CRF binding
to the CRF-BP may be important for the action of CRF axons that likely synapse onto both calbindin-positive
and -negative neurons (Austin et al., 1997), but whereon NMDAR function in VTA neurons was further sup-
ported by the subsequent experiments using ovine CRF, these axons come from, or where the large Ih/calbindin-
negative VTA neurons project to, has yet to be deter-Urocortin, and Urocortin II, which demonstrated that
only binding both CRF-R2 and CRF-BP but not binding mined. One possible source of CRF innervation of the
VTA is the bed nucleus of the stria terminalis, which haseither the CRF-BP or the CRF-R2 alone was capable of
mimicking the effect of CRF on NMDAR function. These a direct excitatory projection to the VTA (Georges and
Aston-Jones, 2002). A detailed understanding of differ-results are quite different from the current understand-
ing of the function of the CRF-BP (Potter et al., 1992), ences between projection sites of calbindin-negative
versus calbindin-positive neurons in the VTA is not avail-which has previously been shown to act merely as a
CRF buffer in the periphery (Linton et al., 1990). How- able. However, it has been suggested that calbindin-
positive neurons may be mainly mesocortical, whereasever, there are several reasons to suppose that CRF-
BP might have additional roles in the brain. In particular, calbindin-negative neurons may be mainly mesoaccum-
bal (for discussion, see Neuhoff et al., 2002). In conclu-icv injections of CRF-BP inhibitors have some behavioral
and neural effects that are inconsistent with them simply sion, whatever the broader implications may be for the
effects of CRF on the dopamine system, the presentelevating CRF levels (Chan et al., 2000; Heinrichs and
Joppa, 2001). findings may open new avenues for potential therapeutic
targets in disorders where CRF and/or dopamine levelsFurther investigations will be required to elucidate the
are decreased.mechanism through which the binding between CRF
and the CRF-BP facilitates the actions of CRF at CRF-
R2. Unfortunately, the detailed anatomy of CRF-BP in Experimental Procedures
the VTA is not known. It may be that CRF-BP is mem-
VTA slices from 21- to 29-day-old C57 mice (Charles River) werebrane bound near the synapse or, alternatively, that it
prepared as previously described (Ungless et al., 2001). In brief,is secreted into the extracellular space and interacts
mice were anesthetized with halothane and then decapitated. A
there in a way that facilitates CRF’s actions (Peto et al., block of tissue containing midbrain was sliced in the horizontal
1999). One possibility is that CRF-BP plays a permissive plane (230 m) in ice-cold low Ca2 solution (containing in mM: 126
role and facilitates the binding of CRF to the CRF-R2. NaCl, 1.6 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 0.625 CaCl2, 18 NaHCO3, and
11 glucose). Slices were transferred to a holding chamber containingAlternatively, the CRF-BP might increase the time that
artificial cerebrospinal fluid (ACSF, in mM: 126 NaCl, 1.6 KCl, 1.2CRF spends in proximity to the CRF-R2. When CRF binds
NaH2PO4, 1.2 MgCl2, 2.5 CaCl2, 18 NaHCO3, and 11 glucose) andto the CRF-BP it forms a stable dimer, and under some
equilibrated at 31	C–34	C for at least 1 hr. Picrotoxin (100 M) was
circumstances, it undergoes conformational modifica- added to the ACSF for recording, to block GABAA receptor-mediated
tions (Lowry et al., 1996). It might be this dimerization inhibitory postsynaptic potentials. All solutions were aerated with
95% O2/5% CO2, and perfused over the slice at a rate of 2.5 ml/and/or conformational change that allows CRF to signal
Neuron
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min. Cells were visualized with an upright microscope using infrared Austin, M.C., Rhodes, J.L., and Lewis, D.A. (1997). Differential distri-
bution of corticotropin-releasing hormone immunoreactive axons indifferential interference contrast (IR-DIC) illumination and whole-cell
voltage clamp recordings were made with an Axopatch 1D amplifier monoaminergic nuclei of the human brainstem. Neuropsychophar-
macology 17, 326–341.(Axon Instruments). Electrodes (2–4 M
) contained in mM: 117 ce-
sium methansulfonic acid, 20 HEPES, 0.4 EGTA, 2.8 NaCl, 5 TEA- Behan, D.P., Heinrichs, S.C., Troncoso, J.C., Liu, X.J., Kawas, C.H.,
Cl, 2.5 MgATP, 0.25 MgGTP (pH 7.2–7.4), 275–285 mOsm. A bipolar Ling, N., and De Souza, E.B. (1995). Displacement of corticotropin
stimulating electrode was placed rostral to the recording electrode releasing factor from its binding protein as a possible treatment for
and was used to stimulate excitatory afferents at 0.1 Hz. Coronal Alzheimer’s disease. Nature 378, 284–287.
hippocampal slices were also prepared and maintained in a similar
Blank, T., Nijholt, I., Eckart, K., and Spiess, J. (2002). Priming of
manner. Extracellular field potentials were recorded in the CA1 re-
long-term potentiation in mouse hippocampus by corticotrophin-
gion and evoked by stimulating the stratum radiatum. All drugs were
releasing factor and acute stress: implications for hippocampus-
obtained from Sigma, except human/rat CRF (Tocris), Antisauvag-
dependent learning. J. Neurosci. 22, 3788–3794.
ine-30 (PolyPeptide) and CP-154,526 (a generous gift from Pfizer).
Bonci, A., and Malenka, R.C. (1999). Properties and plasticity ofCRF fragment (6-33), ovine CRF, Antisauvagine-30, CP-154,526,
excitatory synapses on dopaminergic and GABAergic cells in theU-73122, and Urocortin were first dissolved in DMSO (final concen-
ventral tegmental area. J. Neurosci. 19, 3723–3730.tration 0.1%). EPSCs were filtered at 2 kHz, digitized at 5–10 kHz,
and stored using IgorPro software (Wavemetrics). NMDAR-medi- Chan, R.K.W., Vale, W.W., and Sawchenko, P.E. (2000). Paradoxical
ated EPSCs were recorded at40 mV and measured 20 ms after the activational effects of a corticotropin-releasing factor-binding pro-
stimulation artifact when the EPSC is primarily NMDAR mediated. tein “ligand” inhibitor in the rat brain. Neuroscience 101, 115–129.
Clements, J.D., Lester, R.A., Tong, G., Jahr, C.E., and Westbrook,
Statistical Analysis G.L. (1992). The time course of glutamate in the synaptic cleft. Sci-
In all of the electrophysiological experiments, statistical significance ence 258, 1498–1501.
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Dautzenberg, F.M., and Hauger, R.L. (2002). The CRF peptide family
and post hoc Fisher’s LSD tests were performed where appropriate.
and their receptors: yet more partners discovered. Trends Pharma-
col. Sci. 23, 71–77.
RT-PCR for VTA Slices and Single Cells
Dunn, A.J., and Berridge, C.W. (1987). Corticotropin-releasing factorTwenty-one to twenty-nine-day-old C57 male mice were sacrificed
administration elicits a stress-like activation of cerebral catechol-as for electrophysiology and VTA, septum and cerebellum were
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extension at 72	C for 1 min, and a final incubation at 72	C for 7 min. Georges, F., and Aston-Jones, G. (2002). Activation of ventral teg-
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